Xia Lizi, de Vries Henk, Lenselink Eelke B, Louvel Julien, Waring Michael J, Cheng Leifeng, Pahlén Sara, Petersson Maria J, Schell Peter, Olsson Roine I, Heitman Laura H, Sheppard Robert J, IJzerman Adriaan P
Division of Medicinal Chemistry, LACDR, Leiden University , 2300RA Leiden, The Netherlands.
Medicinal Chemistry, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca , Gothenburg SE-431 83, Sweden.
J Med Chem. 2017 Dec 14;60(23):9545-9564. doi: 10.1021/acs.jmedchem.7b00861. Epub 2017 Nov 21.
We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB receptor and their structure-kinetic relationships (SKRs) were established. Using the recently resolved hCB receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB receptor antagonists in the early phases of drug discovery.
我们报告了一系列作为CB受体拮抗剂开发的1,2 - 二芳基咪唑 - 4 - 甲酰胺衍生物的合成及生物学评价。这些衍生物在放射性配体置换结合试验、[S]GTPγS结合试验以及能够对多种化合物进行相对快速动力学筛选的竞争结合试验中进行了评估。这些化合物在CB受体上表现出高亲和力和多样的动力学特征,并建立了它们的结构 - 动力学关系(SKR)。利用最近解析的hCB受体晶体结构,我们还进行了一项建模研究,该研究揭示了该类配体的亲和力和解离动力学的关键相互作用。我们提供的证据表明,除了亲和力之外,结合动力学的额外知识对于在药物发现的早期阶段选择新的hCB受体拮抗剂是有用的。